Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Zomedica (ZOMDF – Research Report) today and set a price target of $0.25. The company’s shares opened today at $0.03.

Good afternoon, ladies and gentlemen, and welcome to the Zomedica fourth quarter 2024 financial results conference call. (Operator Instructions) This call is being recorded on Thursday ...

Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth ANN ARBOR ...

ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading veterinary health company offering point-of-care diagnostic and ...